Intra-Cellular Therapies ... (ITCI)
NASDAQ: ITCI
· Real-Time Price · USD
131.87
0.00 (0.00%)
At close: Apr 01, 2025, 3:59 PM
Intra-Cellular Therapies Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -16.89M | -26.32M | -16.22M | -15.25M | -28.58M | -24.26M | -42.78M | -44.05M | -44.03M | -53.51M | -86.6M | -72.12M | -85.73M | -76.91M | -68.74M | -52.74M |
Depreciation & Amortization | 109K | 138K | 129K | 132K | 136K | 135K | 123K | 134K | 143K | 170K | 172K | 171K | 146.83K | 133.94K | 125.58K | 127.01K |
Stock-Based Compensation | 16.33M | 17.49M | 16.37M | 13.84M | 14.86M | 14.31M | 13.23M | 10.44M | 11.16M | 11.75M | 12M | 8.11M | 9.38M | 9.53M | 8.62M | 6.78M |
Other Working Capital | 6.64M | -7.52M | 12.51M | -12.97M | 31.83M | -8.37M | 23.22M | 12.73M | 10.14M | -2.35M | 8.66M | -5.29M | 10.11M | -4.41M | -4.26M | -698.76K |
Other Non-Cash Items | -2.97M | -1.83M | 25.22M | 29.34M | 23K | 24K | 23K | -1.72M | 1.19M | 253K | 3.15M | -4.05M | 34.34K | 38.73K | 51.92K | 53.54K |
Deferred Income Tax | n/a | n/a | n/a | n/a | -2.54M | -2.19M | -1.93M | n/a | n/a | -1K | n/a | n/a | -778.78K | -1.59M | -621.92K | -1.09M |
Change in Working Capital | -9.67M | -16M | 2.09M | -30.52M | 14.04M | -13.29M | -5.46M | -24.87M | -7.66M | -12.02M | -23.51M | -14.95M | 3.77M | -10.47M | 1.25M | -900.05K |
Operating Cash Flow | -13.08M | -26.52M | 542K | -34.12M | -2.06M | -25.27M | -36.8M | -60.07M | -39.19M | -53.35M | -94.79M | -82.85M | -73.18M | -79.27M | -59.33M | -47.77M |
Capital Expenditures | 427K | -696K | -53K | n/a | -1K | -268K | n/a | n/a | 28K | -117K | -123K | -566K | -1.24K | -309.25K | -15.24K | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | -19.9M | 19.9M | n/a | n/a | -50.23M | -106.29M | -37.35M | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -257.6M | -312.51M | -88.52M | -81.05M | -104.46M | -136.39M | -65.95M | -108.46M | -115.5M | -90.92M | 273.93M | -826.71M | -69.38M | -35.3M | -85.75M | -34.15M |
Sales Maturities Of Investments | 107.28M | 104M | 96.34M | 97.22M | 151.89M | 116.5M | 160.7M | 92M | 165.74M | 197.21M | -236.58M | 505.24M | 120.89M | 99.38M | 134.56M | 150.42M |
Other Investing Acitivies | n/a | n/a | 7.82M | 16.18M | 47.42M | -19.9M | 94.75M | -16.46M | 50.23M | 106.29M | 37.35M | -321.47M | 51.51M | 64.08M | 48.81M | 116.27M |
Investing Cash Flow | -149.89M | -209.2M | 7.77M | 16.18M | 47.42M | -20.17M | 94.75M | -16.46M | 50.26M | 106.17M | 37.23M | -322.04M | 51.51M | 63.77M | 48.79M | 116.27M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 5.61M | 6.73M | 545.18M | 9.99M | 3M | 2.58M | 8.59M | 3.64M | 2.19M | 5.65M | 5.5M | 8.09M | 7.91M | -296 | n/a | n/a |
Financial Cash Flow | 5.61M | 6.73M | 545.18M | 9.99M | 3M | 2.58M | 8.59M | 3.64M | 2.19M | 5.65M | 5.5M | 441.81M | 7.91M | 591.3K | 1.58M | 1.43M |
Net Cash Flow | -157.36M | -228.99M | 553.49M | -7.95M | 48.37M | -42.86M | 66.53M | -72.89M | 13.26M | 58.47M | -52.06M | 36.93M | -13.76M | -14.9M | -8.95M | 69.93M |
Free Cash Flow | -12.65M | -27.22M | 489K | -34.12M | -2.06M | -25.54M | -36.8M | -60.07M | -39.16M | -53.47M | -94.92M | -83.42M | -73.19M | -79.58M | -59.34M | -47.77M |